{"id":"W4361815918","doi":"10.1158/1078-0432.c.6529460","title":"Data from Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Sierra Oncology; Australian Government; Clovis Oncology; Eisai; BeiGene; Sanofi; Bristol-Myers Squibb; Amgen; AstraZeneca; U.S. Department of Health and Human Services","keywords":"Nivolumab; Ipilimumab; Medicine; Internal medicine; Clinical endpoint; Neuroendocrine tumors; Clinical trial; Progressive disease; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Immunotherapy; Oncology; Phases of clinical research; Surgery; Chemotherapy; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005484016,0.001371239,0.003861593,0.0005745591,0.0004662168,0.001527838,0.0006697308,0.001263583,0.002562701],"category_scores_gemma":[0.004781104,0.0004468888,0.008887075,0.0009936264,0.0004996874,0.0008432335,0.0005284232,0.001539027,0.000473019],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008198774,"about_ca_system_score_gemma":0.001116421,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00107235,"about_ca_topic_score_gemma":0.003181319,"domain_scores_codex":[0.9959453,0.002136534,0.0006115507,0.0005607494,0.0004021456,0.0003438021],"domain_scores_gemma":[0.9958737,0.001567623,0.000855762,0.0008892247,0.0003148806,0.0004989036],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8059608,0.001129634,0.07013777,0.002367243,0.06935745,0.0004876402,0.0001905844,0.002037445,0.008042631,0.0002426837,0.005643449,0.03440271],"study_design_scores_gemma":[0.4088436,0.06466217,0.3853244,0.000613588,0.1142426,0.001493107,0.0004809489,0.003611051,0.003765862,0.001676045,0.01501508,0.000271554],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"dataset","genre_scores_codex":[0.9721664,0.01711578,0.0005628028,0.0006687443,0.0002945175,0.0008933768,0.005169167,0.00004473737,0.003084517],"genre_scores_gemma":[0.9931043,0.001193664,0.0002518454,0.0005580758,0.0002077329,0.0004654315,0.003516915,0.00002407526,0.0006779972],"genre_candidate":"dataset","genre_consensus":null,"teacher_disagreement_score":0.005484016,"threshold_uncertainty_score":0.02900261,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09367127363970035,"score_gpt":0.406981189981038,"score_spread":0.3133099163413377,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}